Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Return on Capital Employed (2019 - 2025)

Allogene Therapeutics' Return on Capital Employed history spans 7 years, with the latest figure at 0.54% for Q3 2025.

  • For Q3 2025, Return on Capital Employed fell 3.0% year-over-year to 0.54%; the TTM value through Sep 2025 reached 0.54%, down 3.0%, while the annual FY2024 figure was 0.49%, 2.0% down from the prior year.
  • Return on Capital Employed for Q3 2025 was 0.54% at Allogene Therapeutics, up from 0.56% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.18% in Q4 2021 and bottomed at 0.56% in Q2 2025.
  • The 5-year median for Return on Capital Employed is 0.49% (2023), against an average of 0.4%.
  • The largest annual shift saw Return on Capital Employed rose 13bps in 2021 before it decreased -26bps in 2023.
  • A 5-year view of Return on Capital Employed shows it stood at 0.18% in 2021, then crashed by -136bps to 0.42% in 2022, then fell by -22bps to 0.51% in 2023, then decreased by 0bps to 0.51% in 2024, then dropped by -5bps to 0.54% in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Return on Capital Employed are 0.54% (Q3 2025), 0.56% (Q2 2025), and 0.54% (Q1 2025).